Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
31JUL

WHO defers vaccine-sharing pact to 2027

3 min read
10:28UTC

WHA79 deferred the Pandemic Agreement's vaccine-sharing annex to 2027, leaving the treaty's equity core inoperative during an emergency that has no licensed product to share.

ScienceDeveloping
Key takeaway

The treaty's vaccine-sharing core stays unfinished until 2027, just as an outbreak with no licensed product needs it.

The 79th World Health Assembly (WHA79) deferred adoption of the Pandemic Agreement's Pathogen Access and Benefit-Sharing (PABS) annex to WHA80 in May 2027, or to an earlier special session if a text is ready 1. The next negotiating round, the seventh Intergovernmental Working Group session (IGWG7), is set for 6 to 17 July 2026 2. PABS is the part of the treaty meant to guarantee that countries which share virus samples receive fair access to the vaccines made from them. Tedros Adhanom Ghebreyesus said real progress had been made, and member states cited a need for more time 3.

This is the second slip in a month: negotiators had already agreed to extend the PABS talks at the resumed sixth IGWG session on 1 May . The annex has stalled because high-income states resist binding sharing obligations they fear will constrain their own manufacturers, the same fault line that has dogged every benefit-sharing negotiation since the 2007 dispute over Indonesian H5N1 samples.

The timing gives the deferral its edge. The treaty's vaccine-sharing core stays inoperative at the exact moment a novel-species emergency with no licensed countermeasure would have tested it. If a Bundibugyo vaccine reaches trials this year, there is still no binding legal route to push doses to the low-income countries carrying the outbreak; allocation stays at the discretion of manufacturers and the buyers WHO can pay first. The world adopted the treaty in 2024 and, two years on, still cannot do the one thing its equity advocates designed it to do.

Deep Analysis

In plain English

When a new dangerous virus emerges, countries need to share samples of it quickly so that scientists around the world can study it and start making vaccines. The problem is that in past pandemics, like H1N1 in 2009, the countries that shared their virus samples did not get any of the vaccines that were made from those samples. Rich countries bought them all first. PABS (Pathogen Access and Benefit-Sharing) is meant to be the rule that fixes this: countries share samples and in return get guaranteed access to vaccines produced from them. The 79th World Health Assembly, which met in Geneva in May 2026, pushed the decision on PABS to a 2027 meeting because member states cannot agree on how the rules would work in practice. During the current Bundibugyo Ebola outbreak, there is no licensed vaccine for this species at all; the PABS negotiations apply to future outbreaks where a sharing-and-access mechanism could make the difference between equitable and inequitable vaccine distribution.

First Reported In

Update #4 · Ebola triples, response misfires

Konrad-Adenauer-Stiftung Geneva Multilateral Dialogue· 24 May 2026
Read original
Different Perspectives
Chinese health authorities
Chinese health authorities
China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.
US public health authorities
US public health authorities
CIDRAP and Dr Andrew Racine, president of the American Academy of Pediatrics, call 2026's 2,318 confirmed measles cases by 24 July the worst year since 1991's 2,126. Zero deaths against three in 2025 and a 7% hospitalisation rate, down from 11%, show record case counts have not brought record severity.
CEPI
CEPI
CEPI put an rVSV-platform vaccine candidate specific to Bundibugyo ebolavirus into trial-production on 31 July, developed by Hilleman Laboratories with MSD manufacturing and IAVI's reference virus, funded up to $8.5m. Eleven weeks into the third-largest Ebola outbreak on record, this is the first species-matched candidate; the licensed vaccine covers only Zaire ebolavirus.
Médecins Sans Frontières
Médecins Sans Frontières
MSF reports sexual-violence care in Ituri is almost non-existent, with 7 of 14 health centres closed or relocated by fighting, as Panzi Hospital logs 646 new survivors in six months, an 85% rise. Withdrawn US funding for post-exposure prophylaxis has left clinics across three provinces without PEP kits for months, a crisis running alongside Ebola, not caused by it.
DRC health workers at Elikya Ebola Treatment Centre
DRC health workers at Elikya Ebola Treatment Centre
Staff at DRC's Elikya Ebola Treatment Centre walked out on 25 July over unpaid wages, the second such action after Rwampara, while unconfirmed suspects occupy up to 64% of the country's isolation beds awaiting lab results. Workers are absorbing a response that has grown faster than its payroll and its labs.
Uganda's Ministry of Health
Uganda's Ministry of Health
Uganda's ministry says it discharged its last confirmed patient on 16 June, completed every contact's 21-day follow-up, and declared the country Ebola-free on 28 July, exactly 42 days later. It names Hon. Dr Chris Baryomunsi, Minister of Health, as overseeing a 20-case, 2-death outbreak it now considers closed.